Logo

Illumina Reports Rise in Q1 Revenues, Flat Losses

Apr 24, 2003

NEW YORK, April 24 - Illumina reported increased revenues for the first quarter late yesterday, amid nearly flat net losses.

 

The San Diegogenotyping and oligonucleotide company's revenues for the quarter ended March 30 totaled $4.3 million, up from $1.3 million for the first quarter of last year.

 

Research and development expenses decreased slightly, to $5.7 million, from $7.1 million in the same period last year.

 

The company's net losses totaled $9.0 million for the quarter, up a hair from the $8.7 million in net losses reported for the first quarter of 2002.

 

At the end of March, Illumina had $60.4 million in cash and investments, a slight decrease from the $66.3 million it reported at the same time last year.

Breaking News
The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.